1. What This Condition Is
Bladder cancer is a malignancy that originates in the cells lining the bladder wall. The most common type is urothelial carcinoma (formerly called transitional cell carcinoma), which arises from the cells that line the bladder, urethra, and urinary tract. Symptoms include blood in the urine (hematuria), frequent urination, painful urination, and pelvic pain. Bladder cancer can range from superficial, low-grade lesions that are managed with periodic surveillance, to invasive cancers requiring radical cystectomy (surgical removal of the bladder), chemotherapy, radiation, or immunotherapy.
Bladder cancer qualifies for VA presumptive service connection through three separate regulatory pathways, covering Vietnam-era veterans, Gulf War and post-9/11 veterans, and PACT Act veterans.
Agent Orange presumptive (38 CFR 3.309(e)): The VA added bladder cancer to the Agent Orange presumptive list in 2021. Veterans who served in Vietnam, the Korean Demilitarized Zone during the qualifying period, or other covered herbicide-exposure locations, and who developed bladder cancer, are entitled to presumptive service connection without proving a medical nexus.
Gulf War and post-9/11 presumptive (38 CFR 3.320a, effective January 2, 2025): A new regulation effective January 2, 2025 establishes bladder and ureter cancer as presumptive conditions for covered veterans who served on or after August 2, 1990 in the Southwest Asia theater of operations or Somalia, or on or after September 11, 2001 in Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Yemen, or Uzbekistan. Veterans covered under 38 CFR 3.320a do not need to establish Agent Orange exposure — the presumption is based on exposure to fine particulate matter and other airborne hazards during qualifying service.
PACT Act presumptive (Public Law 117-168): Veterans exposed to burn pits or other covered toxic exposures at qualifying post-9/11 service locations may also claim service connection under PACT Act authority.
Many veterans diagnosed with bladder cancer do not know they qualify for VA compensation. Veterans diagnosed years or even decades after service are eligible if they have qualifying service and a current diagnosis.
2. VA Rating Criteria
Bladder cancer is rated under 38 CFR § 4.115b, Diagnostic Code 7528 (Malignant Neoplasms of the Genitourinary System).
Active disease or treatment: A 100% rating applies during any period in which bladder cancer is active or under treatment (surgery, chemotherapy, radiation, immunotherapy, or intravesical therapy such as BCG instillation).
Post-treatment: The 100% rating continues for a minimum of six months following the completion of treatment. After that period, the VA conducts a rating examination to assess residual disability.
Residual ratings after treatment: The bladder and its function are evaluated following treatment based on the degree of residual voiding dysfunction under Diagnostic Code 7517 (Bladder, Injury of) and related codes for urinary incontinence and voiding dysfunction:
| Rating | Criteria (Voiding Dysfunction / Urine Leakage) |
|---|---|
| 20% | Requires wearing absorbent material that is changed less than 2 times per day |
| 40% | Requires wearing absorbent material that is changed 2 to 4 times per day |
| 60% | Requires wearing absorbent material that is changed more than 4 times per day |
For veterans who undergo radical cystectomy (bladder removal) and urinary diversion (ileal conduit, neobladder, or other diversion), the urinary diversion itself is rated under the applicable code based on functional impairment.
If bladder cancer is in surveillance (not active treatment) and no significant voiding dysfunction exists, the condition may be rated at 0% if residual disability does not meet a compensable threshold. However, any complications — urinary incontinence from treatment, erectile dysfunction, bowel dysfunction from radiation, or neuropathy from chemotherapy — are each separately ratable.
3. What to Expect at Your C&P Exam
The examiner will review your urology and oncology records, including cystoscopy findings, pathology reports, staging information, and your current treatment status. If your cancer is active or ongoing treatment has recently concluded, the exam will document the active status and confirm the 100% rating.
For a residual exam after treatment ends, be prepared to describe your current urinary function in concrete terms: how often you experience incontinence, whether you wear absorbent pads and how many you use per day, how frequently you urinate, whether you experience urgency, pain, or difficulty emptying, and the functional impact on your daily life and work.
If you underwent cystectomy and urinary diversion, describe the management of your diversion: bag changes, irrigation, skin complications around the stoma site, and any complications that have required additional treatment.
If your cancer required radiation, describe any bowel dysfunction or changes in sexual function that resulted from the radiation field.
4. Evidence You Need to Win
Diagnosis: Pathology reports confirming bladder cancer, cystoscopy reports documenting lesion location and appearance, CT urogram or MRI findings, and all oncology treatment records. The records must clearly document the diagnosis, stage, grade, and treatment history.
Service Record Evidence (Presumptive Claims): Documentation establishing qualifying service in Vietnam, the Korean DMZ during the presumptive period, or another herbicide-exposure location. For PACT Act claims, documentation of service at qualifying locations or duty assignments involving covered exposures.
No Nexus Letter Required for Presumptive Claims: If the Agent Orange or PACT Act presumptive applies, you do not need a physician to connect your diagnosis to your service. Document the diagnosis and qualifying service and file the claim.
Nexus Letter (Non-Presumptive Direct Claims): Veterans with bladder cancer arising from a different service-connected cause (occupational chemical exposure, radiation exposure during service, secondary to another service-connected condition) need a physician's nexus opinion.
DBQ Form: The Genitourinary Conditions DBQ (or the appropriate malignant neoplasm DBQ). Your treating urologist or oncologist should complete this form with current diagnosis, treatment status, and residual functional findings.
Residual Documentation: Records documenting urinary incontinence, pad use, voiding dysfunction, stoma management complications, sexual dysfunction, and bowel changes after treatment. Each residual condition requires separate documentation.
Personal Statement: Describe how bladder cancer and its treatment affect your daily life. For veterans with active disease, describe the treatment burden. For veterans post-treatment, describe the residual voiding dysfunction, pad use, and functional limitations.
Buddy Statements (VA Form 21-10210): Family members or caregivers who can describe your symptom burden, pad changes, and functional limitations provide lay corroboration.
5. Secondary Conditions to Consider
Urinary Incontinence: Post-treatment incontinence from radical cystectomy, radiation, or transurethral resection is ratable separately based on the frequency of pad changes required.
Erectile Dysfunction: Nerve damage from cystectomy, radiation, or chemotherapy commonly produces erectile dysfunction. If service-connected bladder cancer treatment causes ED, Special Monthly Compensation (SMC) may be appropriate rather than a separate disability rating.
Peripheral Neuropathy: Chemotherapy agents used for bladder cancer — particularly cisplatin — cause peripheral neuropathy in the hands and feet. Secondary neuropathy from treatment of service-connected bladder cancer is ratable.
Bowel Dysfunction: Radiation therapy for bladder cancer affects adjacent bowel tissue, causing radiation proctitis, diarrhea, fecal urgency, or bowel incontinence. Secondary bowel conditions are ratable under the digestive system schedule.
Kidney Conditions: Urinary obstruction or diversion complications can cause secondary hydronephrosis or kidney damage. Secondary renal conditions following service-connected bladder cancer treatment may warrant their own rating.
Depression and Anxiety: A cancer diagnosis, the disruption of treatment, and the functional burden of living with urinary incontinence or a urostomy produce significant psychiatric burden. Secondary mental health claims are ratable under 38 CFR 3.310.
6. Common Mistakes That Kill Claims
Not filing because the cancer was diagnosed years after service. The Agent Orange and PACT Act presumptives have no time limit. A veteran diagnosed in 2025 for service in Vietnam in 1968 is entitled to the presumptive if they have the diagnosis and qualifying service. File regardless of how much time has passed since service or since diagnosis.
Not knowing bladder cancer was added to the presumptive list. The VA added bladder cancer to the Agent Orange presumptive list in 2021. Veterans who were previously denied or who never filed because they did not know they qualified should file a Supplemental Claim immediately. Evidence that was not considered before — specifically, the regulatory change making bladder cancer a presumptive — is new and material evidence supporting the Supplemental Claim.
Failing to claim residuals separately. After the 100% active disease rating ends, veterans frequently receive 0% at the residual exam because they do not document incontinence, pad use, voiding dysfunction, or other residuals. Gather residual evidence before the rating exam.
Not documenting pad use precisely. The residual rating formula for voiding dysfunction specifically measures pad changes per day. A physician note saying "incontinence" is not as useful as a note specifying "requires 3 absorbent pads per day." Get that level of specificity in your treatment records before the C&P exam.
Missing the PACT Act pathway for post-9/11 veterans. Younger veterans with bladder cancer may qualify under PACT Act presumptives even without Agent Orange-era service. Verify whether your service locations or duties fall under PACT Act covered exposures and file under that authority.
7. FWD Assist Resources
The following FWD Assist HQ books are directly relevant to a bladder cancer claim:
- Agent Orange: The Complete Vietnam Veterans Claims Guide — covers the expanded presumptive list including bladder cancer, how to document qualifying service, and how to file under the herbicide presumptive
- The PACT Act Playbook — covers PACT Act presumptive coverage for post-9/11 veterans and the expanded exposure locations and conditions under Public Law 117-168
- C&P Exam Prep Guide — covers cancer residual exams and how to document incontinence, voiding dysfunction, and treatment residuals in terms the rating schedule requires
- Secondary Conditions Guide — walks through the neuropathy, bowel dysfunction, and mental health secondary chains from service-connected cancer treatment
All titles are available at fwdassisthq.com.
8. Get Help Without a Claim Shark
Free, accredited help is available through Veterans Service Organizations including the DAV, VFW, American Legion, and AMVETS. County Veterans Service Officers (CVSOs) file and manage claims at no cost.
Charging upfront fees to assist with a VA claim is illegal under 38 U.S.C. § 5905. VA-accredited attorneys and claims agents may charge fees only after an initial VA decision, capped at 20% of past-due benefits under 38 U.S.C. § 5904. No legitimate representative asks for money before your first decision.
Verify accreditation at va.gov/ogc/accreditation.asp.